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Abstract: Agonists of the transmembrane intestinal receptor guanylyl cyclase C (GCC) have 
recently attracted interest as promising human therapeutics. Peptide ligands that can specifically 
induce GCC signaling in the intestine include endogenous hormones guanylin and uroguanylin, 
diarrheagenic bacterial enterotoxins (ST), and synthetic drugs linaclotide, plecanatide, and 
SP-333. These agonists bind to GCC at intestinal epithelial surfaces and activate the receptor’s 
intracellular catalytic domain, an event initiating discrete biological responses upon conversion 
of guanosine-5′-triphosphate to cyclic guanosine monophosphate. A principal action of GCC 
agonists in the colon is the promotion of mucosal homeostasis and its dependent barrier func-
tion. Herein, GCC agonists are being developed as new medications to treat inflammatory bowel 
diseases, pathological conditions characterized by mucosal barrier hyperpermeability, abnormal 
immune reactions, and chronic local inflammation. This review will present important concepts 
underlying the pharmacology and therapeutic utility of GCC agonists for patients with ulcerative 
colitis, one of the most prevalent inflammatory bowel disease disorders.
Keywords: inflammatory bowel disease, GCC agonists, cyclic GMP
Introduction
Ulcerative colitis (UC) is a major clinical syndrome of inflammatory bowel diseases 
(IBDs) and is characterized by chronic mucosal inflammation of the colon. Recurrent 
bloody diarrhea, tenesmus and rectal urgency are the most common symptoms for UC, 
but extraintestinal manifestations may also occur.1 Diagnosis of UC is mainly based 
on intestinal mucosa examination and tissue histopathology following colonoscopy 
and biopsy.1 The worldwide annual incidence of UC is 0.5–25 per 100,000 persons, 
with the highest rates in Western countries and the lowest in the developing world.2 
UC distributes equally among men and women, with a typical onset between 15 and 
40 years of age.1,2 Although the exact pathogenetic mechanism remains unclear, it is 
now apparent that both environmental and genetic factors play relevant etiological roles 
in UC, comprising heterogeneous, multifactorial combinations giving rise to almost 
identical clinical syndromes.3,4 Specifically, any perturbation of the delicate balance 
between commensal bacteria, epithelial barrier functions, and host innate and adaptive 
immunity may result in chronic colonic inflammation.5,6 In the US, about 500,000 
persons are affected by UC, with an annual incidence of 2–7 per 100,000 persons, 
representing a major clinical challenge for the absence of curative pharmacological 
therapies.1
Selective ligands for guanylyl cyclase C (GCC) (Figure 1) include pathological 
agents (heat-stable bacterial enterotoxins; herein referred to as ST), endogenous 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
351
R E v i E w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/DDDT.S32252
Video abstract
Point your SmartPhone at the code above. If you have a 
QR code reader the video abstract will appear. Or use:
http://dvpr.es/14Y43kH
Drug Design, Development and Therapy 2013:7
toxin.7,16 ST causes secretory diarrhea in exposed individuals 
by overactivating the signaling pathway of the intestinal 
receptor GCC, the only confirmed molecular target for ST in 
humans.17 Accordingly, disruption of the gene encoding for 
GCC in mice resulted in resistance to ST-induced intestinal 
secretion and diarrhea.18,19 There is a general consensus 
that after colonizing the intestine of humans or animals 
for survival and growth, bacteria secrete ST to exploit 
the host GCC signaling and disseminate into the external 
environment. Infectious diarrhea caused by ST-producing 
bacteria is a major morbidity factor in areas of poor sanitation 
and crowded conditions, and remains a principal cause of 
travelers’ diarrhea and infant mortality in developing nations.20 
Despite improved mechanistic understanding, the frequency 
of these diarrheal diseases has not significantly changed 
during the past decades.20 Provocatively, the worldwide risk of 
travelers’ diarrhea inversely correlates with the incidence of 
colon cancer, and developing countries appear to be protected 
from colorectal transformation.21 This cancer resistance has 
been suggested to reflect, in part, longitudinal exposure of 
endemic populations to enterotoxigenic infections22 and the 
ability of ST to regulate the cell cycle transition, and suppress 
proliferation of intestinal epithelial cells.21,23 In this model, 
ST and the host GCC represent an evolutionary-conserved 
symbiotic system conferring mutual beneficial effects to 
microbes and mammals.
Endogenous hormones
After ST, two endogenous peptide ligands for GCC with 
primary amino acid sequences similar to the enterotoxin were 
identified. First, a substance from rat intestinal extracts that 
stimulated GCC signaling in human colon adenocarcinoma 
cells was isolated and named guanylin.24 Subsequently, 
a guanylin-like peptide was isolated from the urine and 
intestine of opossum and humans and named uroguanylin.25,26 
Guanylin and uroguanylin are principally synthesized in 
the intestine, circulate in the bloodstream, are excreted in 
the urine, and induce diuresis, natriuresis, and kaliuresis, 
suggesting they act as endocrine hormones of an enteric-renal 
system regulating salt and water homeostasis.27 Importantly, 
these peptides, exhibiting 15 (guanylin) or 16 (uroguanylin) 
residues and two intrachain disulfide bridges (Figure 1), 
selectively bind and activate GCC in apical brush-border 
membranes of intestinal epithelial cells, although with less 
potency than ST.8,25,26 They are encoded by genes organized 
in a tail-to-tail configuration on human chromosome 1p, and 
secreted by intestinal mucosal cells as proforms, which are 
activated upon carboxyl terminus cleavage.8,28 Intriguingly, 
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ST Linaclotide
PlecanatideUroguanylin
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Figure 1 The guanylyl cyclase C agonists. 
Notes: Known primary amino acid structures of the agonists of guanylyl 
cyclase C. Residues shown in green on the structures on the right indicate amino 
acid substitutions in synthetic ligands compared with respective biological homologs. 
The amino acid sequence for ST reflects that of the heat-stable enterotoxin isoform 
STh produced by Escherichia coli.
hormones (guanylin and uroguanylin) and, most importantly 
for this review, therapeutic drugs (linaclotide, plecanatide, 
and SP-333).7–10 Mostly short peptides of 14–19 amino acids, 
these GCC agonists share close structural and functional 
similarities, including intrachain disulfide bonds required 
for biological activity, pH stability, protease resistance, 
and poor systemic bioavailability when administered 
orally. ST and its artificial analog, linaclotide, contain three 
disulfide bonds and are considered super-agonists for GCC, 
as they maximally activate the receptor-dependent signal 
transduction machinery.9,11,12 Plecanatide and SP-333, in turn, 
are synthetic analogs of the endogenous agonist uroguanylin, 
and together with guanylin, exhibit only two intrachain 
disulfide bonds.8,10 Recently, the utility of GCC agonists 
as IBD therapeutics has been proposed,13,14 and SP-333 is 
currently being developed for the treatment of UC.10 This 
review will discuss the pharmacological potential of GCC 
agonists as promising novel drugs for patients with UC.
Pharmacological agonists of GCC
Bacterial enterotoxins
The f irst GCC ligand identif ied was the heat-stable 
enterotoxin ST (Figure 1), a diarrheagenic agent produced 
by intestinal pathogens such as Escherichia coli, Klebsiella 
sp., and Yersinia enterocolitica.15 ST comprises a family of 
small peptides (ranging from 17 to 53 amino acids) sharing 
a conserved carboxyl terminal region of 13 residues, with 
six cysteines forming three disulphide bridges that define 
the tertiary structure and physicochemical properties of the 
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ligand effects appear to depend on extracellular pH, and 
uroguanylin is 100-fold more potent than guanylin at acidic 
pH (5.0–5.5), while guanylin is fourfold more potent than 
uroguanylin at basic pH (8.0).29 Both endogenous GCC 
ligands exhibit a crypt-to-villus gradient of expression, 
which is maximal in small intestinal villi and superficial 
epithelial cells of the colon.28,30,31 However, uroguanylin is 
more abundant in the proximal tracts of the intestine, while 
guanylin is highly expressed in the colon and rectum.28,30,31 
Also, guanylin and uroguanylin expression undergoes 
circadian rhythm (highest at night),32 is induced by osmotic 
stress33 and zinc deficiency,34 and is downregulated by low 
salt intake.35 These regulatory mechanisms and distribution 
patterns of expression suggest a complex, spatially distinct 
role for these peptides in the intestine. In this context, 
guanylin and uroguanylin are considered autocrine/
paracrine hormones, which control local fluid balance and 
the homeostasis of the intestinal mucosa, including crypt 
renewal dynamics, cell differentiation and metabolism, 
and epithelial barrier function (Figure 2).17,36 Their crucial 
function as promoters of the normal intestinal epithelial cell 
phenotype is further underscored by the GCC ligandopenia 
characterizing early colorectal carcinogenesis,37,38 and the 
anticancer activity of oral replacement therapy with GCC 
agonists in the gut.22
Therapeutic drugs
As our understanding of the number of critical physiological 
functions played by the biological ligands grows significantly 
(Figure 2), it is becoming apparent that GCC agonists possess 
great translational potential for human intestinal diseases. 
Currently, three artificial GCC ligands are being exploited 
as oral therapeutics for chronic idiopathic constipation, 
constipation-predominant irritable bowel syndrome and 
IBD. The first synthetic GCC agonist entering the clinic has 
been linaclotide (Ironwood Pharmaceuticals Inc, Boston, 
MA, USA and Forest Laboratories Inc, New York, NY, USA), 
an ST analog cyclopeptide of 14 amino acids (Figure 1) 
which increases intestinal motility and fluid secretion, 
while decreasing visceral pain in preclinical models.9 
Linaclotide is converted in vivo by carboxypeptidase A 
into the active 13mer metabolite MM-419447, which 
contributes to linaclotide’s pharmacodynamics.39 Recently, 
linaclotide has been approved in the US for the treatment 
of patients with chronic idiopathic constipation and 
irritable bowel syndrome with constipation, wherein this 
GCC agonist is behaving as a safe, reliable, and effective 
drug in improving disease-specific abdominal and bowel 
symptoms.39–42 In that context, a 26-week Phase III trial 
in 804 patients with constipation-predominant irritable 
bowel syndrome demonstrated that linaclotide (N of treated 
patients, 401) significantly ameliorated constipation and 
disease severity (clinical responders: linaclotide group, 
33.7% versus placebo group, 13.9%), while inducing 
significant, sustained improvement of worst abdominal 
pain and abdominal discomfort, fullness, cramping, and 
bloating.42 Of note, with the exception of diarrhea (mostly 
of mild/moderate intensity; linaclotide group, 19.7% versus 
placebo group, 2.5%), which is an expected extension of 
linaclotide pharmacology, the incidence of adverse events 
was not significantly different in linaclotide-treated patients 
compared with the placebo controls.42 After linaclotide, two 
additional artificial GCC agonists, plecanatide (a 16mer) 
(Figure 1) and SP-333 (Synergy Pharmaceuticals Inc, New 
York, NY, USA), have entered the drug developmental 
stage.10 Both synthetic analogs of uroguanylin, but of 
superior potency, plecanatide and SP-333 are exhibiting 
promises as gastrointestinal therapeutics.10 Plecanatide 
is in clinical development for the treatment of chronic 
idiopathic constipation (Phase IIb/III studies ongoing) 
and constipation-predominant irritable bowel syndrome 
(Phase I study planned).10 In the completed Phase I–II 
clinical trials, plecanatide significantly ameliorated patients’ 
bowel movements and symptoms.10 In contrast, SP-333 is 
being investigated specifically for the treatment of IBD in 
patients with UC, and is currently in the preclinical stage 
of development.10 In studies employing animal models of 
IBD, SP-333 attenuated colitis-associated events through 
the downregulation of locally released autacoids mediating 
the inflammatory response.10
Biological
GCC ligands 
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Metabolic
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DNA damage
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Figure 2 Physiological functions regulated by endogenous GCC agonists in the 
intestine. 
Notes: The diagram indicates the principal putative biological responses elicited by 
endogenous hormones guanylin and uroguanylin upon binding and activation of GCC 
on intestinal brush-border membranes.
Abbreviation: GCC, guanylyl cyclase C.
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Signal transduction mechanisms
The receptor
The principal pharmacological target for ST, guanylin, 
uroguanylin, and their synthetic analogs is GCC. Discovered 
as the “heat stable enterotoxin receptor,”15 GCC is encoded by 
the gene GUCY2C on human chromosome 12p12. GUCY2C 
homologs are widely conserved across species including 
mammals, reptiles, and birds, suggesting a fundamental role 
for GCC in organismal biology.43–45 Beyond discrete neuronal 
cells in the central nervous system,46,47 in mammals, GCC 
is uniquely expressed at apical, brush-border membranes of 
intestinal epithelial cells from the duodenum to the rectum, 
uniformly distributed in crypts, villi, and mucosal surfaces.17 
GCC, a member of membrane-bound guanylyl cyclases, 
is a homodimeric transmembrane enzyme exhibiting 
conserved functional domains (Figure 3A), including: 
(1) the extracellular domain for specific ligand binding; 
(2) a single transmembrane domain with an hydrophobic 
α-helix region; (3) a short juxtamembrane domain with a 
G-protein consensus sequence; (4) the kinase homology 
domain, which binds adenosine triphosphate and regulates 
ligand-receptor aff inity; (5) a hinge region, probably 
mediating catalytic subunit dimerization; (6) the catalytic 
domain, which mediates the conversion of guanosine 
triphosphate to cyclic guanosine monophosphate (cGMP); 
and (7) a carboxyl terminal tail with key regulatory functions, 
including modulation of cyclase activity, cytoskeletal 
anchoring, and receptor internalization.17 The extracellular 
domain of GCC possesses a unique amino acid sequence, 
and glycosylation and oligomerization sites, which affect the 
specificity, stability and efficacy of ligand-receptor binding.17 
In this context, upon agonist binding to the extracellular 
domain of GCC, an intramolecular conformational change 
is induced and transmitted along the transmembrane and 
cytoplasmic domains to the carboxyl terminal catalytic 
site, resulting in a manifold increase of intracellular cGMP 
concentration over the basal state.15,17
The downstream targets
Cyclic GMP represents the sole intracellular second 
messenger for GCC agonists. A variety of key cellular 
responses are mediated by cGMP,17 which regulates virtually 
all major cytoplasmic signaling networks.48 In intestinal 
epithelial cells, GCC is the principal source of cGMP, and 
ligand–GCC interactions in concert with distinct elimination 
mechanisms (phosphodiesterase-dependent hydrolysis; 
transporter-dependent efflux) define the type, intensity, 
and duration of cellular cGMP rises and effects. In this 
way, elegant spatio-terminal determinants regulate crucial 
physiological responses in intestine by imposing maximal 
cGMP signaling. Examples of these include the increased 
endogenous ligand expression at superficial epithelial 
compartments, which mediates maturation dynamics,28,31 and 
the GCC baso-apical expression gradient within cells, which 
ensures fluid regulation at luminal membrane borders.17
The functional consequences of GCC agonist-induced 
cGMP elevations in intestinal epithelial cells reflect the 
selective targeting of downstream molecular effectors 
(Figure 3B), exhibiting two evolutionarily distinct allosteric 
binding sites for cGMP. One cGMP binding site is present in 
cGMP- and cAMP-dependent protein kinases (protein kinase 
G [PKG] and protein kinase A [PKA], respectively) and in 
cyclic nucleotide gated (CNG) cation channels, while the 
other is expressed in cGMP-regulated phosphodiesterases 
(PDEs). Differential tissue expression and intracellular 
compartmentalization of these cGMP targets enable 
Extracellular
domain
Transmembrane
domain
Juxtamembrane
domain
Kinase homology
domain
Hinge region
Catalytic domain
Carboxyl terminal
tail
BA GCC
GTP
CFTR
PDE
PKG
CNG
VASP
cAMP
Cl−
Ca2+
CaR
PKA
cGMP
Figure 3 GCC and its downstream targets. (A) The domain structure of GCC. (B) Key proximal effectors activated by GCC in intestinal epithelial cells upon catalytic 
conversion of GTP to cGMP.
Abbreviations: cAMP, cyclic adenosine monophosphate; CaR, calcium-sensing receptor; CFTR, cystic fibrosis transmembrane conductance regulator; cGMP, cyclic 
guanosine monophosphate; CNG, cyclic nucleotide gated channel; GCC, guanylyl cyclase C; GTP, guanosine-5′-triphosphate; PDE, phosphodiesterases; PKA, protein kinase 
A; PKG, protein kinase G; VASP, vasodilator-stimulated phosphoprotein.
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selectivity and accuracy of signal transmission and execution. 
PKG and PKA principally mediate regulation of intestinal 
fluid homeostasis and cytoskeletal organization by GCC 
ligands at membrane regions (Figure 3B). PKG is a Ser/Thr 
protein kinase comprising two subtypes, the soluble PKG I, 
with two isoforms Iα and Iβ, widely expressed in tissues, 
and the particulate PKG II, abundant in the intestine.49 PKA 
is a tetrameric kinase preferentially activated by cAMP.17 
PKG II and PKA activation by GCC agonists mediate water 
and electrolyte secretion by inducing phosphorylation and 
opening of the cystic fibrosis transmembrane conductance 
regulator (CFTR), with subsequent Cl− efflux into the 
intestinal lumen.50–52 In this way, endogenous GCC ligands 
act as “fluidity sensors” that provide optimal intestinal 
mucosa hydration through induction of net secretion 
of water, NaCl, and HCO
3
−.17 PKG I, in turn, mediates 
effects of GCC ligands on the cytoskeleton and contractile 
apparatus.17 A particularly crucial PKG target in these actions 
is the vasodilator-stimulated phosphoprotein (VASP), an 
actin binding protein controlling cytoskeletal remodeling, 
cell shape, and adhesion contacts in intestinal epithelial 
cells.53 Herein, GCC agonists induce rapid PKG I-mediated 
phosphorylation of Ser239 in the carboxyl terminal VASP 
domain,54 thereby suppressing F-actin polymerization and 
membrane protrusion formation.53,55,56
Further, CNG channels represent a principal intracellular 
effector for inhibition of proliferation by GCC agonists in 
intestine (Figure 3B). CNG channels are heterotetrameric 
proteins of α- and β-subunits, which mediate cGMP-
dependent Na+ and Ca2+ influx.57 GCC signaling through CNG 
channels slows intestinal cell cycle progression by inducing 
intracellular Ca2+ influx and cytosolic Ca2+ elevations.21 An 
important mechanism by which intracellular Ca2+ by GCC 
agonists suppresses proliferation in intestinal cells is the 
translocation of calcium-sensing receptors to membrane 
compartments.58 Calcium-sensing receptor is a key mediator 
of tumor inhibitory activities by luminal Ca2+, principally 
reflecting its role as a regulator of intestinal cell maturation 
dynamics. Thus, ligand–GCC signaling may act as a 
regulatory system promoting physiological actions by dietary 
Ca2+ in the gut, including cytostasis and the proliferation 
to differentiation transition along the crypt–villus axis.21,58 
Finally, cGMP-regulated PDEs (eg, PDE2, PDE5, PDE6, and 
PDE10) are enzymes specialized in the cleavage of the cyclic 
nucleotide phosphodiester bond.17 In intestinal epithelial 
cells, these PDEs are principally involved in the modulation 
or termination of biological signaling by GCC agonists, 
and in the cross-talk between cGMP- and cAMP-dependent 
pathways (Figure 3B).52,59
GCC signaling in colonic 
mucosal integrity
During the last decade, the appreciation of the biological 
significance of GCC and its ligands for intestinal mucosa 
homeostasis is increased substantially (Figure 2), and from a 
mere fluidity sensor mechanism, the agonist/GCC pathway 
may now be considered a fundamental promoter of the 
intestinal mucosa integrity and its dependent barrier function. 
In this regard, the columnar epithelial cell monolayer covering 
the inner surface of the colorectum provides a complex 
chemical and physical barrier protecting the host from its 
harmful external environment, including pathogens, toxins, 
and food bioproducts.60 This monolayer is sealed by tight 
junctions restricting barrier permeability and comprises three 
cell lineages arising from self-perpetuating stem cells located 
at colonic crypt bases, including absorptive colonocytes, 
mucus-producing goblet cells, and hormone-secreting 
enteroendocrine cells.61 Maintenance of the balance between 
proliferation, migration, and differentiation along the colonic 
crypt-surface axis is central in preserving an intact epithelial 
barrier function, and alterations in those cell homeostatic 
dynamics compromise the bowel mucosal integrity, thereby 
favoring inflammatory responses and IBD by unchecked 
exposure of the sterile host compartment to dangerous 
luminal antigens.62 Elimination of GCC signaling disrupts 
the epithelial lineage crypt-surface balance in the mouse 
colon, reflected by hyperplastic proliferative compartments 
with fast-cycling and fast-migrating progenitor cells,63,64 and 
poorly developed differentiated compartments, characterized 
by incomplete phenotypic and metabolic maturation and self-
repair programs.64–66 In particular, loss of GCC resulted in a 
fewer number of colonic goblet cells, with reduced production 
of mucin and intestinal trefoil factor.64 This is significant 
because UC patients exhibit fewer, malfunctioning goblet 
cells whose pathological recapitulation in mouse models 
results in loss of mucosal integrity, inflammation, and 
spontaneous colitis.67 Moreover, mucin and intestinal trefoil 
factor are key components of the gut-coating mucus layer 
mediating epithelial barrier protection and post-injury 
restitution, and their defective production or activity in mice 
causes increased intestinal permeability and susceptibility 
to chronic colonic inflammation.68 The contribution to 
optimal mucus barrier function is further underscored by the 
ability of ligand-dependent GCC signaling through CFTR to 
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induce secretion of NaCl and HCO
3
−,17,50 critical electrolytes 
controlling the rheological properties of the mucus layer and 
its proper interaction with the adjacent colonic microbiota.69 
Importantly, secretion of these electrolytes at colonic surfaces 
is often dysregulated in UC patients.70
Beyond effects on lineage- and mucus-dependent 
functions, GCC signaling protects intestinal barrier 
integrity by promoting tight junction-mediated epithelial 
cell sealing. Elimination of GCC or uroguanylin in mice 
increased intestinal permeability and inflammation through 
myosin light chain kinase activation and tight junction 
disassembly, with reduced claudin-2 and JAM-A levels.13 
Accordingly, induction of GCC signaling with GCC agonists 
enhanced tight junction assembly, reduced intestinal barrier 
permeability and protected mice from chemical-induced 
colitis.14 A key mechanism mediating regulation of epithelial 
cell tight junctions by GCC is the inhibition of v-akt murine 
thymoma viral oncogene homolog 1 (AKT-1) activity, coupled 
with increased expression of junctional proteins occludin and 
claudin-4.14 In this context, it is reasonable to speculate that 
the likely candidate as the proximal molecular effector of 
GCC-mediated intestinal barrier functions is PKG. In support 
of this notion, PKG I-mediated VASP phosphorylation 
represents a well established paradigm underlying cell–cell 
junction integrity and tissue barrier protection.71,72 Notably, 
in intestinal epithelial cells, GCC agonists suppress 
cytoskeletal remodeling at dynamic membrane regions, the 
process driving epithelial junction disassembly,73 by inducing 
PKG-dependent VASP phosphorylation.53 Moreover, ligand-
mediated GCC signaling through CFTR, which controls 
electrolyte secretion and intestinal barrier maintenance by 
the mucus layer, is a PKG II-dependent phenomenon.17,50 
Together, these observations underscore the central role of 
the GCC pathway in support of intestinal barrier integrity, 
including its protection from or its restitution following injury. 
In one model, similarly to other intestinal regulatory peptides, 
GCC endogenous ligands guanylin and uroguanylin are to 
be considered “mucosal barrier guardians,” whose signal 
transduction dysregulation may contribute to inflammation 
and IBD.74 Conversely, iatrogenic induction of colonic 
GCC signaling with administration of specific agonists as 
therapeutics may hold great promise for the prevention of 
further damage, or mucosal barrier restitution in patients 
with UC (Figure 4).10,14
GCC agonists as UC therapeutics
Current pharmacological remedies for UC include 
5-aminosalicylic acid, corticosteroids, cyclosporine, 
and infliximab, a monoclonal antibody blocking pro-
inflammatory tumor necrosis factor-α.1 Although these 
drugs may induce symptom remission and successfully 
prevent disease progression,75 ∼30% of patients with severe 
UC are resistant to pharmacological therapy and require 
colectomy.76,77 The global risk of colectomy for UC patients 
is ∼9% over 10 years.76 Common curative surgery consists of 
total proctocolectomy with ileal J-pouch anal anastomosis.76 
However, this procedure is associated with high rates (∼20%) 
of postoperative complications,76 including abscesses, 
sepsis, fistulas, infertility, and sexual dysfunction.78,79 Thus, 
innovative drug development programs for UC are warranted. 
In that context, GCC agonists could be exploited as a 
unique class of therapeutics for IBD and UC in particular. 
In the “leaky gut” hypothesis, intestinal hyper-permeability 
resulting from disruption of mucosal barrier integrity is a 
principal pathogenetic event underlying abnormal immune 
responses to luminal antigen exposure and IBD (Figure 4, 
left panel).60,62,80,81 Reestablishment of epithelial barrier 
function, in turn, could arrest pathogenetic processes of 
inflammation thereby preventing or treating IBD.81 As GCC 
signaling protects lineage-dependent homeostasis along the 
colonic crypt-surface axis,36,64 activation of that pathway 
by its specific ligands could restore normal environment-
immune interactions regulated by the epithelial monolayer 
(Figure 4, right panel).60 Moreover, the ability of GCC 
agonists to specifically reinforce the colonic barrier through 
the regulation of the superficial mucus layer17,50 and epithelial 
tight junctions14 may predict their utility as novel drugs 
for the chemoprevention and treatment of patients with 
barrier-dependent intestinal inflammation (Figure 4).62,81 
Mucus layer
Homeostatic environment-immune
responses 
Cell lineage
commitment Tight junction
Proliferation Differentiation
GCC agonists
Insufficient
mucus layer
Abnormal immune responses,
inflammation 
Disruption of cell
lineage homeostasis 
Tight junction
disassembly
Proliferation Differentiation
Epithelial
hyperpermeability
Loss of colonic barrier integrity
Figure 4 GCC agonists as ulcerative colitis therapeutics. 
Notes: in ulcerative colitis, abnormal immune responses and colonic inflammation 
reflect inappropriate luminal antigen exposure for disruption of the mucosal barrier 
integrity (left panel). Pathogenetic mechanisms underlying loss of intestinal barrier 
function, in turn, include mutually reinforcing processes of cell lineage imbalance, 
defective mucus layer, tight junction disassembly and epithelial cell hyper-permeability 
(left panel). Administration of GCC agonists reconstitutes normal environment-
immune interactions by restoring the colonic mucosal barrier integrity, in part, 
through the promotion of cell lineage-dependent homeostasis, optimal superficial 
mucus layer and epithelial cells’ tight junctions (right panel).
Abbreviation: GCC, guanylyl cyclase C.
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Additionally, expression of endogenous GCC ligands 
guanylin and uroguanylin is significantly reduced in affected 
UC tissues compared with healthy subjects,82 supporting 
the notion that restoration of the dormant GCC pathway 
with exogenous administration of GCC agonists may be an 
effective strategy to tissue restitution in UC patients.
In striking contrast with the above considerations, 
a nonsynonymous single nucleotide polymorphism in 
GUCY2C conferred a dominant phenotype on affected 
members of a Norwegian family, characterized by ligand-
dependent hyperactivation of GCC signaling, chronic 
diarrhea, and susceptibility to intestinal inflammation and 
IBD.83 Accordingly, ∼10% of travelers experiencing acute 
diarrhea from exposure to Escherichia coli producing the 
GCC super-agonist ST develop post-infectious chronic 
intestinal symptoms and irritable bowel syndrome.84 
Further, the artificial ST analog linaclotide compared poorly 
with other drugs in protecting isolated pig jejunum from 
ischemia-induced intestinal barrier disruption,85 and mice 
deficient in GUCY2C exhibited reduced mucosal damage 
and inflammation following chemical-induced colitis.86 
Beyond confounding variability in experimental models, 
apparent conflicting observations on the role of GCC in 
inflammatory gut disorders could be reconciled if one 
assumes that only physiological levels of ligand-dependent 
GCC activation mediate intestinal mucosa protection. In 
this model, activation of the wild-type GCC receptor with 
the endogenous ligands ensures beneficial GCC signaling 
underlying normal intestinal biology. In contrast, both 
dormancy and hyperactivation of the GCC pathway would 
disrupt mucosal homeostasis and result in bowel disease 
susceptibility. Thus, administration of adequate dosages 
of GCC agonists should mimic homeostatic functions of 
endogenous ligands and oppose intestinal barrier disruption, 
prevent inflammatory responses and treat IBD-associated 
pathological events. Of significance, SP-333, the GCC agonist 
currently under therapeutic development for the treatment of 
patients with UC, is an artificial analog of the endogenous 
GCC ligand uroguanylin.10 SP-333 is behaving as a highly 
effective drug in preclinical mouse models of UC, wherein 
it is reducing colonic inflammatory damage induced with 
various chemicals, in part, through the downregulation of pro-
inflammatory cytokines including interleukins 4, 5, and 23, 
and tumor necrosis factor.10 Finally, prolonged stimulation 
of GCC with its ligands produces cellular refractoriness 
to biological effects of GCC agonists,59 pointing toward 
selective temporal administration schedules as yet another 
critical variable, apart from drug concentrations, to consider 
for optimal translation of GCC-targeted strategies into UC 
patients’ therapeutics.
Conclusion
In UC, disruption of homeostatic balance between intestinal 
microflora, epithelial barrier permeability and host 
immune responses underlies colitis and tissue damage.5,6 
It is suggested that unsupervised exposure of the sterile 
subepithelial compartment to luminal antigens promotes 
chronic inflammatory processes and recurrent symptoms.62 
There is a need for innovative drug development programs 
in UC, wherein ∼9% of patients undergo colectomy 
as a result of severe disease that is resistant to current 
pharmacological therapy.1,76 GCC agonists are attractive 
novel UC therapeutics because of their unique mechanism 
of action, which would enable restoration of homeostatic 
signaling circuits promoting colonic mucosa integrity. 
In this way, GCC agonists will fill an unmet need in the 
pharmacological anti-UC armamentarium by targeting one 
causal mechanism of chronic colonic inflammation, abnormal 
mucosal permeability.81
Beyond inflammation in the gut, intestinal barrier 
protection by GCC and its agonists also reduces local 
and systemic DNA damage and tumorigenesis.14,65 Not 
surprisingly, UC patients exhibit a higher incidence of 
colorectal cancer.1 An inverse epidemiological association 
exists between colon cancer and the risk for enterotoxigenic 
infections,21 and UC is less common in geographic areas 
where those infections are endemic.2 Thus, it is tempting 
to speculate that intermittent longitudinal exposure to the 
exogenous GCC agonist ST may contribute to protect 
resident populations from both UC and colorectal cancer. 
These observations also suggest that GCC agonists might 
have a broad therapeutic utility, from local inflammation and 
tumorigenesis chemoprevention to systemic protective actions 
against genotoxicity and transformation.14 Of relevance, oral 
administration of GCC agonists is a safe, effective, and well 
tolerated medication in patients with chronic constipation,39–42 
underscoring the clinical utility for these agents as human 
therapeutics. Together, these considerations support the great 
significance and translational potential of GCC agonists for 
the management of UC patients, reflecting the emergent role 
of this new class of drugs as promoters and protectors of the 
mucosal barrier integrity in the colon.
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